Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR1 | P21817 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epiryanodine SCHEMBL159872 | 0.99 | RYR1 (1.00) | RYR1 | |
| Epiryanodine SCHEMBL25722480 | 0.99 | RYR1 (1.00) | RYR1 | |
| Epiryanodine SCHEMBL118946 | 0.99 | RYR1 (1.00) | RYR1 | |
| Epiryanodine SCHEMBL20100627 | 0.99 | RYR1 (1.00) | RYR1 | |
| Epiryanodine SCHEMBL5933502 | 0.99 | RYR1 (1.00) | RYR1 | |
| Epiryanodine SCHEMBL31236365 | 0.99 | RYR1 (1.00) | RYR1 | |
| Epiryanodine SCHEMBL13912554 | 0.99 | RYR1 (1.00) | RYR1 | |
| Epiryanodine SCHEMBL13479886 | 0.99 | RYR1 (1.00) | RYR1 | |
| Epiryanodine SCHEMBL20104624 | 0.99 | RYR1 (1.00) | RYR1 | |
| Epiryanodine SCHEMBL4318989 | 0.98 | RYR1 (0.98) | RYR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392344-A4 | METHOD OF MODULATING THE ACTIVITY OF CALCIUM CHANNELS IN CARDIAC CELLS AND REAGENTS THEREFOR | UNIV AUSTRALIAN (AU) | 2005-09-21 | — | — | EP | claimed |
| US-20050049198-A1 | Method of modulating the activity of calcium channels in cardiac cells and reagents therefor | AUSTRALIAN NATIONAL UNIVERSITY, THE (AU) | 2005-03-03 | — | — | US | claimed |
| CN-1516596-A | Methods of modulating calcium channel activity in cardiac cells and agents therefor | ���Ĵ���ѧ | 2004-07-28 | — | — | CN | claimed |
| EP-1392344-A1 | METHOD OF MODULATING THE ACTIVITY OF CALCIUM CHANNELS IN CARDIAC CELLS AND REAGENTS THEREFOR | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2004-03-03 | — | — | EP | claimed |
| WO-2002092119-A1 | METHOD OF MODULATING THE ACTIVITY OF CALCIUM CHANNELS IN CARDIAC CELLS AND REAGENTS THEREFOR | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2002-11-21 | — | — | WO | claimed |
| WO-2023224927-A2 | COMPOSITIONS AND METHODS FOR TREATING A CARDIAC DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2021121447-A1 | SYSTEM AND METHOD FOR AXONAL INJURY ASSAYS | FAKULTNI NEMOCNICE U SV. ANNY V BRNE (CZ) | 2021-06-24 | — | — | WO | disclosed |
| US-20210147497-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-05-20 | — | — | US | disclosed |
| CN-111194212-A | Methods and compositions for treating or preventing catecholamine-sensitive polymorphic ventricular tachycardia | 儿童医疗中心有限公司 | 2020-05-22 | — | — | CN | disclosed |
| EP-3648755-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA | Children's Medical Center Corporation (US) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019010386-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-01-10 | — | — | WO | disclosed |
| EP-2945646-A1 | ESTROGEN RECEPTOR INHIBITORS | Shapiro, David J. (US) | 2015-11-25 | — | — | EP | disclosed |
| WO-2000004037-A1 | UNCOUPLING PROTEIN 4 (UCP-4) AND METHODS OF USE | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
| US-5854392-A | β APP-C100 receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-29 | — | — | US | disclosed |
| WO-1998045313-A1 | NOVEL UNCOUPLING PROTEIN AND METHODS OF USE | AMYLIN PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1997018230-A9 | CLONING AND EXPRESSION OF BETA APP-C100 RECEPTOR (C100-R) | — | 1997-07-31 | — | — | WO | disclosed |
| WO-1997018230-A1 | CLONING AND EXPRESSION OF BETA APP-C100 RECEPTOR (C100-R) | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0659217-A1 | CLONING AND EXPRESSION OF $g(b)APP-C100 RECEPTOR | Bristol-Myers Squibb Company (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994005811-A9 | CLONING AND EXPRESSION OF βAPP-C100 RECEPTOR | — | 1994-05-11 | — | — | WO | disclosed |
| WO-1994005811-A1 | CLONING AND EXPRESSION OF βAPP-C100 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147497-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA | TNNI3, TNNT2, TNNC1 | RYR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.